Glycotest is a liver disease diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis. Founded in 2012 by NetScientific plc on technology innovated by two experts in the fields of liver disease and glycobiology−Professors Timothy Block and Anand Mehta at Drexel University College of Medicine and the Baruch S. Blumberg Institute, we have exclusive, world-wide rights to over 50 patent-protected serum glycoprotein biomarkers, biomarker panels and algorithms, and novel assay technology that exploit sugar-based disease signals. The Company’s lead test for curable early-stage liver cancer has significantly outperformed the current standard blood test in multiple preliminary clinical studies. Our mission is to revolutionize the care and treatment of the at-risk chronic liver disease population, including the rapidly growing population with NASH.
ABOUT US
ABOUT GLYCOTEST
Our Company
First Test–HCC Panel for Early Detection
Our first test is the HCC Panel which is designed for the early detection of Hepatocellular Carcinoma (HCC). The HCC Panel is a surveillance test for patients who have had chronic liver disease and are at a higher risk of progressing to HCC. If HCC is detected early, it can be curable, but unfortunately, current test methods are not sensitive enough to catch most early-stage HCC. The HCC Panel test is currently being used in a 776 patient clinical validation study which we expect to be completed in mid-2023. We plan to launch the HCC Panel to improve the care of chronic liver disease patients provided by hepatologists and gastroenterologists.
OUR TEAM
Management Team and Board
Dr. Ilian Iliev
Dr. Ilian Iliev is CEO of NetScientific and Managing Director of EMV Capital, which is a fully-owned subsidiary of NetScientific. Co-founded by Ilian, EMV…
Ed Hooper
Ed Hooper is Executive Director, General Counsel and Group Company Secretary of NetScientific, providing legal, strategic and commercial support to the Group and its…
John Clarkson
John Clarkson is an experienced business professional and qualified accountant, who had a successful early career working in various financial, audit and management positions…
Ms. Pei JIANG
Ms. Pei JIANG graduated with Master degree of lmmunology from Fudan University in 2012. She joined Shanghai Fosun Long March Medical Science Co., Ltd…
Charles Swindell
Charles Swindell has over 30 years of experience in biopharmaceutical R&D, product development, and senior management in entrepreneurial life science companies. He has…
Scientific and Medical Advisors
Timothy Block, PhD, Innovator and Advisor
Dr. Block is Co-Founder and President of the Baruch S. Blumberg Institute and the Hepatitis B Foundation, which established the Institute in 2003 to…
Anand Mehta, DPhil, Innovator, Advisor, Member, Medical Advisory Board
Dr. Mehta is SmartState Endowed Chair of Proteomic Biomarkers and Professor, Medical University of South Carolina. He received his graduate degree in Biochemistry from…
David Chernoff, MD, Chair, Medical Advisory Board
Dr. Chernoff has served as acting Chief Medical Officer for several start-up molecular diagnostic companies including XDx, CardioDx, and Tethys Bioscience. Previously, he was…
Scott Friedman, MD, Member, Medical Advisory Board
Scott Friedman is Chief of the Division of Liver Diseases and Dean for Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai,…
Douglas Dieterich, MD, Member, Medical Advisory Board
Douglas Dieterich is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York with appointments in the Divisions of Liver…
SHAREHOLDERS
NetScientific PLC
NetScientific plc (AIM: NSCI) is an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies.
NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.
NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.
NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.
For more information about NetScientific PLC, see: www.netscientific.net
Fosun Pharma
About Fosun Pharma
Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Adhering to the mission of improving human health, Fosun Pharma’s business covers all key sectors of the healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices, and medical diagnosis, as well as pharmaceutical distribution and retail. Fosun Pharma always regards innovation as the driving force for its business growth.
For more information about Fosun Pharma, see: www.fosunpharma.com
Drexel University
About Drexel University
Founded in 1891 in Philadelphia, Drexel is a comprehensive urban university of more than 24,000 students, and it is one of Philadelphia’s largest private employers. Drexel is a leader in experiential, technology-infused education, enriched by the nation’s premier cooperative- education program. The University’s research enterprise was recently elevated to R1 status in the Carnegie Classification of Institutions of Higher Education — a rank that denotes the highest level of research activity, held by just 37 private universities around the country. The University disclosed 84 total new inventions and received 36 new United States patents in fiscal year 2020.
For more information about Drexel University, see: www.drexel.edu
Baruch S. Blumberg Institute
About Blumberg Institute
The Baruch S. Blumberg Institute is an independent, nonprofit (501c3) research institute established in 2003 by the Hepatitis B Foundation to conduct discovery research and nurture translational biotechnology in an environment conducive to interaction, collaboration and focus. It is particularly focused on discovery of new therapeutics to manage chronic hepatitis B and liver cancer, and early detection of liver disease. Working with academic partners, its scientists have pioneered discovery of new strategies to manage chronic hepatitis B and to detect liver cancer. It was renamed in 2013 to honor Baruch S. Blumberg, who won the Nobel Prize for his discovery of the hepatitis B virus and co-founded the Hepatitis B Foundation. The Baruch S. Blumberg Institute created and manages the Pennsylvania Biotechnology Center, one of the nation’s leading incubators for life sciences startup companies..
For more information about Blumberg Institute see: www.blumberginstitute.org
GLYCOTEST PRESENTATION
A New Paradigm for Early Diagnosis and Surveillance For Liver Cancer
